For US Patients
For US Patients

For patients 12 years of age and older living with anti-AChR or anti-MuSK antibody-positive generalized myasthenia gravis (gMG)

With IMAAVY® (nipocalimab-aahu)
disease control can last*

As measured by improvement in daily function using the MG-ADL scale in a 24-week clinical study

*MG-ADL improved on average by 4.7 points with IMAAVY + current gMG treatment
and 3.3 points with placebo + current gMG treatment from baseline to Weeks 22, 23, and 24.

AChR=acetylcholine receptor; MG-ADL=Myasthenia Gravis Activities of Daily Living;
MuSK=muscle-specific tyrosine kinase.

Achieve significant improvement

in daily function† and muscle weakness‡

IMAAVY + current gMG treatment§:

4.7

average point improvement

in MG-ADL score†

Patients taking placebo + current gMG treatment experienced a 3.3-point improvement on average

Items in the MG-ADL scale include:

  • Talking
  • Chewing
  • Swallowing
  • Breathing
  • Brushing teeth or hair
  • Rising from chair
  • Double vision
  • Eyelid droop

This was measured using results averaged from Weeks 22, 23, and 24 of the study compared to baseline.

IMAAVY + current gMG treatment§:

4.9

average point improvement

in QMG score‡

Patients taking placebo + current gMG treatment experienced a 2.1-point improvement on average

Items in the QMG scale include:

  • Double vision and upper eyelid droop
  • Ability to drink water
  • Counting out loud
  • Grip strength
  • Face and neck muscle strength
  • Breathing capacity
  • Arm strength
  • Leg strength

This was measured using results averaged from Weeks 22 and 24 of the study compared to baseline.

†Measured using the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale, which assesses the impact of gMG on 8 daily-function items that are typically affected in gMG.

‡Measured using the Quantitative Myasthenia Gravis (QMG) scale, which assesses muscle weakness based on 13 items.

§In the study, patients were given IMAAVY + their current gMG treatment or placebo + their current gMG treatment. Current therapies included acetylcholinesterase inhibitors (85%), steroids (66%), or non-steroidal immunosuppressive therapies (54%), taken together or separately.

See the results
Quote start

I’m back to being able to do some MG activities of daily living independently now.

Quote end

Allison, IMAAVY patient

Allison is a paid spokeswoman for J&J. She was not a clinical trial participant for IMAAVY. In consideration of the time Allison spent participating in this activity, she was paid honoraria by Johnson & Johnson.

Get personalized support tailored
to your unique needs

Once you and your healthcare provider have decided that IMAAVY is
 right for you, IMAAVY withMe is here for you and your loved ones with
free personalized support when and where you may need it.